. 212 hits and the data from the GUS differentiation and Alamar blue viability assays. GUS activity S/B = GUS signal of drug treated samples to signal of background samples, optimal concentration for GUS activation, IC 50 : 50% inhibitory concentration. NA: not applicable (there was no GUS signal). All assays were performed with a 40 h exposure time on T. b. brucei. GUSone. The initial parasite density was 7×10 5 /ml in the GUS assay and 2.5×10 5 /ml in the Alamar blue assay. Figure S1 . Z'-factor of each plate in the MTS. The high Z'-factor of 0.9 in average indicates a highly robust assay. Controls: trypanosomes with cis-aconitate (CA) served as the positive control and trypanosomes without any drug served as the negative control. Anti-trypanosomal control drugs tested in the GUS reporter assay and the viability assay. The standard drugs melarsoprol, pentamidine, suramin, nifurtimox and fexinidazole were tested for viability (Alamar Blue) and for GUS activation with a 40 hour drug exposure time and initial parasite density of 5×10 5 GUSone trypanosomes /ml. All compounds were tested over a ≥1,000-fold concentration range with 2x dilution steps. The dose response plots are from a single experiment. Among the standard trypanocidal drugs tested, only melarsoprol gave a GUS signal (S/B>2). No GUS activation was observed following exposure to pentamidine, suramin, nifurtimox and fexinidazole, including non-toxic concentrations. At highly trypanocidal concentrations the GUS signal is below the background signal (trypanosomes without drug) resulting in S/B ratio <1. Figure S4 . Melarsoprol induces GUS expression up to 2x over background. The starting trypanosome density was 8×10 5 parasites/ml for 16 h and 24 h, 5×10 5 parasites/ml for 40 h and 2.5×10 5 parasites/ml for 48 h exposure. The S/B was 2 fold at 22.5 ng/ml after 40 h exposure or at 11.25 ng/ml after 48 h. S/B: Ratio of GUS signal of melarsoprol-treated trypanosomes to GUS signal of untreated trypanosomes. Bars indicate standard deviations of S/B from at least three independent assays. Pentamidine is slower acting at high drug concentrations (>10-fold IC 50 ) and a wider concentration range is required to cover low to strong inhibition than for melarsoprol and the 4 DIP compounds ( Figure S6 ). Figure S8 . Loss of VSG of standard drugs at 37°C. The density of the VSG coat was monitored by staining with anti-VSG221 antibodies and flow cytometry. Assays were performed in triplicate with a 24 h drug exposure time. To display the dose-dependent VSG shifts, representative curves of different drug concentrations were plotted together with the corresponding untreated control. MFI: median fluorescence intensity. T/B: VSG changes are expressed as a ratio of the MFI after treatment to the MFI of the untreated control. Full flow cytometry data are available in Table S5 .
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